This evening we watched Stryker drop -2.3% to a price of $290.95 per share. The large-cap Medical Instruments & Supplies company is now trading -8.83% below its average target price of $319.13. Analysts have set target prices ranging from $295.0 to $345.0 per share for Stryker, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.1%, and a short ratio of 1.89. The company's insiders own 6.47% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 80.3% of Stryker's shares being owned by this investor type.
Institutions Invested in Stryker
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Vanguard Group Inc | 8% | 30,665,520 | $8,922,133,418 |
| 2023-09-30 | Blackrock Inc. | 7% | 26,078,897 | $7,587,655,400 |
| 2023-09-30 | Greenleaf Trust | 5% | 19,328,638 | $5,623,667,462 |
| 2023-09-30 | State Street Corporation | 4% | 14,000,189 | $4,073,355,160 |
| 2023-09-30 | Wellington Management Group, LLP | 4% | 13,663,496 | $3,975,394,327 |
| 2023-09-30 | Price (T.Rowe) Associates Inc | 3% | 11,899,667 | $3,462,208,258 |
| 2023-09-30 | Capital Research Global Investors | 3% | 10,336,520 | $3,007,410,620 |
| 2023-09-30 | Geode Capital Management, LLC | 2% | 6,264,910 | $1,822,775,640 |
| 2023-09-30 | Bank Of New York Mellon Corporation | 2% | 6,241,855 | $1,816,067,788 |
| 2023-09-30 | FMR, LLC | 2% | 5,972,582 | $1,737,722,805 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Stryker.
